Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes

Lorena Pochini1, Mariafrancesca Scalise, Cesare Indiveri

  • 1Department of Cell Biology, University of Calabria, Via P.Bucci 4c, 87036 Arcavacata di Rende, CS, Italy.

Insights

Omeprazole inhibits the carnitine transporter OCTN2 through both covalent and non-covalent mechanisms. This interaction, primarily at the external site, affects carnitine transport, with implications for in vivo drug effects.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Membrane Transport

Background:

  • The carnitine transporter OCTN2 plays a crucial role in carnitine uptake.
  • Omeprazole is a widely used proton pump inhibitor with potential off-target effects.

Purpose of the Study:

  • To investigate the interaction of omeprazole with the carnitine transporter OCTN2.
  • To elucidate the mechanisms and kinetics of omeprazole-mediated inhibition of OCTN2.

Main Methods:

  • Reconstitution of OCTN2 transporter in liposomes.
  • Inhibition assays using proteoliposomes and brush border vesicles.
  • Kinetic analysis and dose-response studies.

Main Results:

  • Omeprazole inhibited OCTN2-mediated carnitine transport via both covalent and non-covalent mechanisms.
  • Covalent inhibition involved reaction with cysteine residues and was partially reversible by DTE.
  • Non-covalent inhibition was competitive, while covalent inhibition was non-competitive, with distinct IC50 and Ki values.

Conclusions:

  • Omeprazole interacts with the external site of the OCTN2 transporter.
  • The substrate facilitated the covalent interaction of omeprazole with OCTN2.
  • The findings suggest potential in vivo implications for omeprazole's effect on carnitine homeostasis.

Related Concept Videos

Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport01:19

Drug Absorption Mechanism: Carrier-Mediated Membrane Transport

Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...